Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Open Access
- 15 December 2022
- journal article
- research article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 16, 1489
Abstract
Targeting BRAF V600E in metastatic colorectal cancer: where are we today? Rodrigo Motta Guerrero1a, Veronica Arnao Labajos1b, Sophia Lozano Ballena2c, CarlKeywords
This publication has 58 references indexed in Scilit:
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerAnnals of Oncology, 2014
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerEuropean Journal of Cancer, 2014
- Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in MelanomaThe American Journal of Pathology, 2013
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trialsEuropean Journal of Cancer, 2012
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerJournal of Clinical Oncology, 2011
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerCancer, 2011
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnnals of Oncology, 2011
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialThe Lancet Oncology, 2010
- BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genesOncogene, 2005